Prior Authorization Criteria

LOTRONEX® *(alosetron)* PA Criteria:

**FDA Indication:** Treatment of severe diarrhea-predominant irritable bowel syndrome (IBS) in women.

Select the diagnosis:
- ☐ Severe diarrhea-predominant irritable bowel syndrome

ICD-10 code(s): ________________________________

**Initial approval:** 12 week approval

- ☐ Yes  ☐ No  Age of patient is within the age range as recommended by the FDA label.
  - AND
- ☐ Yes  ☐ No  Female gender at birth
  - AND
- ☐ Yes ☐ No  Diagnosis of severe diarrhea-predominant irritable bowel syndrome (IBS) and at least one the following:
  - ☐ Yes  ☐ No  frequent and severe abdominal pain/discomfort
  - ☐ Yes  ☐ No  frequent bowel urgency or fecal incontinence
  - ☐ Yes  ☐ No  disability or restriction of daily activities due to IBS
  - AND
- ☐ Yes  ☐ No  Symptoms for at least 6 months
  - AND
- ☐ Yes  ☐ No  Anatomical or biochemical abnormalities of the GI tract have been excluded
  - AND

Has NOT responded adequately to ALL conventional therapies as follows:

- ☐ Yes  ☐ No  Bulk forming fiber supplements
- ☐ Yes  ☐ No  Anti-diarrhea medications
- ☐ Yes  ☐ No  Antispasmodics: dicyclomine and/or hyoscyamine
- ☐ Yes  ☐ No  Preferred drugs diarrhea predominant IBS

**Reauthorization:** 52 weeks approval based on the following criteria:

- ☐ Yes  ☐ No  Symptoms of IBS continue to persist
  - AND
- ☐ Yes  ☐ No  Documentation of positive clinical response

Next page
**Dosage and Administration:** (0.5-1mg twice daily)

- Starting dose: 0.5 mg twice daily with meals.
  - Patients who become constipated should stop taking Lotronex until the constipation resolves.
  - Restart at one 0.5 mg tablet by mouth once a day. If constipation recurs, discontinue immediately.

- If after 4 weeks the dosage does not adequately control IBS symptoms, increase to one 1 mg tablet by mouth twice a day.

- Discontinue Lotronex in patients who have not had adequate control of IBS symptoms after 4 weeks of treatment with 1 mg twice a day.

**Contraindications:**

- Chronic or severe constipation or sequelae from constipation, intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation and/or adhesions, ischemic colitis, impaired intestinal circulation, thrombophlebitis, hypercoagulable state, Crohn's disease, ulcerative colitis, diverticulitis, severe hepatic impairment

- Concomitant use of fluvoxamine

**Other Important information to Consider:**

Lotronex also carries the following black box warnings:

- Infrequent but serious gastrointestinal adverse reactions have been reported with the use of Lotronex. These events, including ischemic colitis and serious complications of constipation, have resulted in hospitalization and, rarely, blood transfusion, surgery, and death.

- Lotronex is indicated only for women with severe diarrhea predominant irritable bowel syndrome (IBS) who have not responded adequately to conventional therapy.

- Discontinue Lotronex immediately in patients who develop constipation or symptoms of ischemic colitis. Do not resume Lotronex in patients who develop ischemic colitis. Patients who have constipation should immediately contact their prescriber if the constipation does not resolve after LOTRONEX is discontinued. Patients with resolved constipation should resume LOTRONEX only on the advice of their treating prescriber.